Yuan Rui, Wang Tianming, Zhang Linling, Jeevithan Lakshmi, Wang Chunxiao, Li Xiaohui, Wu Wenhui
Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Department of Biomaterials Engineering, Faculty of Health Sciences, UCAM-Universidad Catolica San-Antonio de Murcia, 30107 Murcia, Spain.
Int J Mol Sci. 2025 Mar 30;26(7):3209. doi: 10.3390/ijms26073209.
L-arginine, a semi-essential amino acid, is well-documented for its role in nitric oxide (NO) synthesis, its anti-inflammatory properties, and its modulation of immune responses. Studies suggest it may improve gut barrier function and reduce inflammation in conditions such as colitis or sepsis. However, its specific efficacy in diabetic enteropathy (a complication of diabetes involving intestinal dysfunction, inflammation, and neuropathy) is less studied. To verify whether L-arginine and silkworm pupae components have a role in the treatment of diabetic enteropathy via the regulation of other cytokines and suppression of CD4+ T lymphocyte proliferation, a special medical-purpose formula containing both of these components was tested. For the first time, we have integrated L-arginine and silkworm pupae protein into enteral nutrition formulations for testing its anti-inflammatory potential. We have found that these formulations can improve the characteristics of diabetic intestinal inflammation through nutrient-modulating effects and nutritional efficacy. In addition, L-arginine (L-arginine, L-arg) enhances the immunomodulatory effects of special medical purpose formulas for diabetes mellitus. We utilized an oxidative stress model of small intestinal epithelial cells induced by high glucose and an inflammation model of the small intestine triggered by lipopolysaccharide in mice. The aim was to further investigate the protective effects of L-arginine and enteral nutritional preparations derived from silkworm pupae protein components on the intestinal tract. This research seeks to establish a theoretical foundation for understanding how L-arginine and these nutritional preparations regulate intestinal inflammation in vivo.
L-精氨酸是一种半必需氨基酸,其在一氧化氮(NO)合成中的作用、抗炎特性以及对免疫反应的调节作用都有充分的文献记载。研究表明,它可能改善肠道屏障功能,并减轻结肠炎或脓毒症等病症中的炎症。然而,其在糖尿病性肠病(糖尿病的一种并发症,涉及肠道功能障碍、炎症和神经病变)中的具体疗效研究较少。为了验证L-精氨酸和蚕蛹成分是否通过调节其他细胞因子和抑制CD4+T淋巴细胞增殖在糖尿病性肠病治疗中发挥作用,测试了一种含有这两种成分的特殊医用配方。我们首次将L-精氨酸和蚕蛹蛋白整合到肠内营养制剂中,以测试其抗炎潜力。我们发现这些制剂可以通过营养调节作用和营养功效改善糖尿病肠道炎症的特征。此外,L-精氨酸(L-arginine,L-arg)增强了糖尿病专用医用配方的免疫调节作用。我们利用高糖诱导的小鼠小肠上皮细胞氧化应激模型和脂多糖触发的小鼠小肠炎症模型。目的是进一步研究L-精氨酸和源自蚕蛹蛋白成分的肠内营养制剂对肠道的保护作用。本研究旨在为理解L-精氨酸和这些营养制剂如何在体内调节肠道炎症建立理论基础。